<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693404</url>
  </required_header>
  <id_info>
    <org_study_id>18-01019</org_study_id>
    <nct_id>NCT03693404</nct_id>
  </id_info>
  <brief_title>Effects of a Surgical Site Injection on Pain Scores and Narcotic Use After Orthopaedic Trauma Surgery</brief_title>
  <official_title>Effects of a Surgical Site Injection on Pain Scores and Narcotic Use After Orthopaedic Trauma Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, randomized, single-blind, placebo-controlled, single-center study of the
      effects of surgical site injection on pain and narcotic utilization in participants who
      undergo surgery for lower extremity fractures. 200 participants with lower extremity
      fractures who are admitted for operative fixation will be included in the study. Participants
      will be randomized to receive either a pain cocktail injection around the fracture site and
      surrounding tissues or control (no injection). An analysis of pain scores, rehabilitation
      progress, length of stay, narcotic utilization, and satisfaction scores will be performed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>amount (mg) of narcotics (oral morphine mg equivalents) used</measure>
    <time_frame>6 Months</time_frame>
    <description>Number of mgs taken of oral morphine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>duration of narcotic use</measure>
    <time_frame>6 Months</time_frame>
    <description>Number of days on morphine post surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>patient reported pain scores using VAS score</measure>
    <time_frame>6 Months</time_frame>
    <description>Using a ruler, the score is determined by mea-suring the distance (mm) on the 10-cm line between the &quot;no pain&quot; anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Pertrochanteric Fracture</condition>
  <arm_group>
    <arm_group_label>Spinal Anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>General Anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will receive no injection into area surrounding the fracture site</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marcaine, Duramorph , ketorolac</intervention_name>
    <description>Subjects in the SSI group will receive an injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.</description>
    <arm_group_label>Spinal Anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine (Marcaine)</intervention_name>
    <description>0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.</description>
    <arm_group_label>Spinal Anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>General Anesthetics</intervention_name>
    <description>Placebo group will only receive standard of care general anesthesia</description>
    <arm_group_label>General Anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lower extremity fracture including femoral neck, intertrochanteric, sub-trochanteric,
             and femoral shaft fracture

        Exclusion Criteria:

          -  Pregnant women

          -  Treatment with Arthroplasty

          -  Patients who receive a peripheral nerve block

          -  Patients who receive intra-op or post-op ketamine

          -  Patients with concomitant TBI or MR

          -  Polytrauma patients

          -  Pathologic Fractures

          -  Patients who live greater than 10 miles from NYU or who will not be followed by an NYU
             provider

          -  Patients with a contraindication to any of the medications on the study list due to
             other medical problems such as renal or liver disease or due to allergy/intolerance

          -  Patients with prior extremity weakness resulting from stroke or other neurological
             condition

          -  Prior or current history of narcotic use

          -  Patients with advanced dementia

          -  NYUMC Students, Residents, Faculty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Leucht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rivka Ihejirika, MD</last_name>
    <phone>646 501 0291</phone>
    <email>rivka.ihejirika@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York University Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karan Patel</last_name>
      <phone>646-501-0291</phone>
      <email>karan.patel@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Philip Leucht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Anesthetics, General</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication.</ipd_time_frame>
    <ipd_access_criteria>Requests should be directed to Philipp.Leucht@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

